Trials / Active Not Recruiting
Active Not RecruitingNCT05918133
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
Detailed description
PD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and enhance cancer growth and metastasis. PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM8002 | IV infusion |
| DRUG | nab-paclitaxel | IV infusion |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
- First posted
- 2023-06-26
- Last updated
- 2025-03-11
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05918133. Inclusion in this directory is not an endorsement.